Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism

Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.

NCT Number	NCT07328230
Lead Sponsor	Chinese Academy of Medical Sciences, Fuwai Hospital Collaborators: Second Affiliated Hospital of Nanchang University, First Affiliated Hospital of Chengdu Medical College
Conditions	Idiopathic Hyperaldosteronism, Hyperaldosteronism
Enrollment	172 participants
Start Date	2022-08-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-09